US EditionPublished • loading... • Updated
Staff shortages, tariffs threaten $350B U.S. pharma investment boom
Summary by CDR – Chain Drug Review
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Staff shortages, tariffs threaten $350B U.S. pharma investment boom
GREENVILLE, S.C. — A $350 billion investment boom in U.S. pharmaceutical manufacturing is being constrained not by cost, but by a shortage of skilled labor, according to a new report from Global Location Strategies (GLS). The firm’s 2026 Best Places for Pharmaceutical Manufacturing Insights Report highlights the key factors shaping investment in the country’s therapeutic biologics industry amid a broader “Reindustrialize America” movement.GLS: S…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
